1380087-89-7

Basic information

• Product Name: 2-[6-(4-Chloro-phenyl)-1-Methyl-4H-3-oxa-2,5-diaza-benzo[e]azulen-4-yl]-acetaMide
• Synonyms: 2-[6-(4-Chloro-phenyl)-1-Methyl-4H-3-oxa-2,5-diaza-benzo[e]azulen-4-yl]-acetaMide;BET bromodomain inhibitor;2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide;CPI-0610;(4S)-6-(4-Chlorophenyl)-1-methyl-4H-isoxazolo[5,4-d][2]benzazepine-4-acetamide;CPI0160
• CAS NO: 1380087-89-7
• Molecular Formula: C20H16ClN3O2
• Molecular Weight: 365.81294
• EINECS: -0
• Product Categories: Inhibitors
• Mol File: 1380087-89-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 622.8±55.0 °C(Predicted)
• Appearance: /
• Density: 1.41±0.1 g/cm3(Predicted)
• PKA: 16.07±0.40(Predicted)
• CAS DataBase Reference: 2-[6-(4-Chloro-phenyl)-1-Methyl-4H-3-oxa-2,5-diaza-benzo[e]azulen-4-yl]-acetaMide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[6-(4-Chloro-phenyl)-1-Methyl-4H-3-oxa-2,5-diaza-benzo[e]azulen-4-yl]-acetaMide(1380087-89-7)
• EPA Substance Registry System: 2-[6-(4-Chloro-phenyl)-1-Methyl-4H-3-oxa-2,5-diaza-benzo[e]azulen-4-yl]-acetaMide(1380087-89-7)

Safety Data

• Hazardous Substances Data: 1380087-89-7(Hazardous Substances Data)

Usage

Description

2-[6-(4-Chloro-phenyl)-1-Methyl-4H-3-oxa-2,5-diaza-benzo[e]azulen-4-yl]-acetamide is a complex organic compound characterized by its unique molecular structure. It is a derivative of benzo[e]azulen, which is a type of azulen compound known for its diverse applications in various fields due to its unique chemical properties.

Uses

Used in Pharmaceutical Industry:
2-[6-(4-Chloro-phenyl)-1-Methyl-4H-3-oxa-2,5-diaza-benzo[e]azulen-4-yl]-acetamide is used as a BET Bromodomain Inhibitor for inhibiting myeloma cell proliferation in clinically relevant models. This application is significant in the development of novel therapeutic strategies for the treatment of various types of cancer, particularly myeloma.
The compound's ability to inhibit myeloma cell proliferation suggests that it may play a crucial role in the regulation of gene expression and cellular processes associated with cancer cell growth and survival. By targeting the BET Bromodomain, this compound has the potential to disrupt the molecular pathways that contribute to the development and progression of myeloma, offering a promising avenue for the development of new cancer treatments.

Upstream product

• 1380089-99-5 tert-butyl (S)-2-(1-methyl-6-oxo-5,6-dihydro-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetate 

Relevant articles and documents

Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials

In recent years, inhibition of the interaction between the bromodomain and extra-terminal domain (BET) family of chromatin adaptors and acetyl-lysine residues on chromatin has emerged as a promising approach to regulate the expression of important disease-relevant genes, including MYC, BCL-2, and NF-κB. Here we describe the identification and characterization of a potent and selective benzoisoxazoloazepine BET bromodomain inhibitor that attenuates BET-dependent gene expression in vivo, demonstrates antitumor efficacy in an MV-4-11 mouse xenograft model, and is currently undergoing human clinical trials for hematological malignancies (CPI-0610).

CRYSTALLINE FORMS OF 2-((4S)-6-(4-CHLOROPHENYL)-1-METHYL-4H-BENZO[C]ISOXAZOLO[4S5-E]AZEPIN-4-YL)ACETAMIDE

The present disclosure relates to a crystalline form of 2-((4S)-6-(4-chlorophenyl)-1- methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, which is useful as an inhibitor of bromodomain-containing proteins. The present disclosure also provides pharmac